1-20 of 32
Gordon B. Mills
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer

Yuping Yin, Weizhen Liu, Qian Shen, Peng Zhang, Lulu Wang, Ruikang Tao, Hang Li, Xianxiong Ma, Xiangyu Zeng, Jae-Ho Cheong, Shumei Song, Jaffer A. Ajani, Gordon B. Mills, Kaixiong Tao, Guang Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (8): 1439–1450.
https://doi.org/10.1158/1535-7163.MCT-18-0833
Published: 01 August 2019
View articletitled, The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer
Open the PDF for The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Prospective Clinical Sequencing of Adult Glioma

Siyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, Xiaojing Wang, Fang Wang, Agda Karina Eterovic, Kenna R. Mills Shaw, Funda Meric-Bernstam, Gregory N. Fuller, Ken Chen, Roel G. Verhaak, Gordon B. Mills, W.K. Alfred Yung, Shiao-Pei Weathers, John F. de Groot
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (5): 991–1000.
https://doi.org/10.1158/1535-7163.MCT-18-1122
Published: 01 May 2019
View articletitled, Prospective Clinical Sequencing of Adult Glioma
Open the PDF for Prospective Clinical Sequencing of Adult Glioma in another window
Includes: Supplementary data
Journal Articles

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 642–655.
https://doi.org/10.1158/1535-7163.MCT-18-0413
Published: 01 March 2019
View articletitled, Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Open the PDF for Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness in another window
Includes: Supplementary data
Journal Articles

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea, Huiqin Chen, Joohyuk Sohn, Napa Parinyanitikul, Tina Primeau, Kim-Anh Do, George F. Vande Woude, John Mendelsohn, Naoto T. Ueno, Gordon B. Mills, Debu Tripathy, Ana M. Gonzalez-Angulo
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (2): 399–412.
https://doi.org/10.1158/1535-7163.MCT-18-0710
Published: 04 February 2019
View articletitled, Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Open the PDF for Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

Sarina A. Piha-Paul, Wendy Wen Xiong, Tyler Moss, Rosa M. Mostorino, Shelby Sedelmeier, Kenneth Hess, Siqing Fu, David Hong, Filip Janku, Daniel Karp, Aung Naing, Shubham Pant, Jordi Rodon, Vivek Subbiah, A M. Tsimberidou, Timothy Yap, Milind Javle, Coya Tapia, Kenna R. Shaw, Karina Eterovic, Gordon B. Mills, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A096.
https://doi.org/10.1158/1535-7163.TARG-17-A096
Published: 01 January 2018
View articletitled, Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)
Journal Articles

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L. Dale, Scott Boiko, Tony Cheung, Jingwen Zhang, Shenghua Wen, Lillian Castriotta, Deborah Lawson, Michael Collins, Larry Bao, Miika J. Ahdesmaki, Graeme Walker, Greg O'Connor, Tammie C. Yeh, Alfred A. Rabow, Jonathan R. Dry, Corinne Reimer, Paul Lyne, Gordon B. Mills, Stephen E. Fawell, Michael J. Waring, Michael Zinda, Edwin Clark, Huawei Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2563–2574.
https://doi.org/10.1158/1535-7163.MCT-16-0141
Published: 01 November 2016
View articletitled, AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Open the PDF for AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Filip Janku, Helen J. Huang, Bart Claes, Gerald S. Falchook, Siqing Fu, David Hong, Nishma M. Ramzanali, Giovanni Nitti, Goran Cabrilo, Apostolia M. Tsimberidou, Aung Naing, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Veronica R. Holley, Ralph G. Zinner, Vivek Subbiah, Rajyalakshmi Luthra, Scott Kopetz, Michael J. Overman, Bryan K. Kee, Sapna Patel, Benoit Devogelaere, Erwin Sablon, Geert Maertens, Gordon B. Mills, Razelle Kurzrock, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1397–1404.
https://doi.org/10.1158/1535-7163.MCT-15-0712
Published: 02 June 2016
View articletitled, BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
Open the PDF for BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System in another window
Includes: Supplementary data
Journal Articles

Abstract PR03: The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition

Taru Muranen, Laura M. Selfors, Carson C. Thoreen, Lisa L. Gallegos, Jonathan L. Coloff, Gordon B. Mills, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): PR03.
https://doi.org/10.1158/1538-8514.PI3K14-PR03
Published: 06 July 2015
View articletitled, Abstract PR03: The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition
Journal Articles

Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway

Edward Curry, Azadeh Cheraghchi-Bashi-Astaneh, Michelle Chen, Paula Cunnea, De Sousa Camila, Elaina Maginn, Yan Dai, Edison Liu, Harpreet Wasan, Gordon B. Mills, David Bowtell, Hani Gabra, Euan A. Stronach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): A47.
https://doi.org/10.1158/1538-8514.PI3K14-A47
Published: 06 July 2015
View articletitled, Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway
Journal Articles

Abstract IA08: Functionalizing the cancer genome

Gordon B. Mills
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): IA08.
https://doi.org/10.1158/1538-8514.PI3K14-IA08
Published: 06 July 2015
View articletitled, Abstract IA08: Functionalizing the cancer genome
Journal Articles

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Tuhina Mazumdar, Lauren A. Byers, Patrick Kwok Shing Ng, Gordon B. Mills, Shaohua Peng, Lixia Diao, You-Hong Fan, Katherine Stemke-Hale, John V. Heymach, Jeffrey N. Myers, Bonnie S. Glisson, Faye M. Johnson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (11): 2738–2750.
https://doi.org/10.1158/1535-7163.MCT-13-1090
Published: 03 November 2014
View articletitled, A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Open the PDF for A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D

Ningning He, Nayoung Kim, Mee Song, Choa Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyunga Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills, Sukjoon Yoon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (10): 2463–2473.
https://doi.org/10.1158/1535-7163.MCT-14-0297
Published: 02 October 2014
View articletitled, Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Open the PDF for Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D in another window
Includes: Supplementary data
Journal Articles

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Funda Meric-Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, Jose A. Pérez-Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pilar Eroles, Juan Antonio Barrera, Octavio Burgues, Ana M. Lluch, Xiaofeng Zheng, Aysegul Sahin, Philip J. Stephens, Gordon B. Mills, Maureen T. Cronin, Ana M. Gonzalez-Angulo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1382–1389.
https://doi.org/10.1158/1535-7163.MCT-13-0482
Published: 05 May 2014
View articletitled, Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Open the PDF for Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C199: Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules.

Huifang Guo, Meng Gao, Yiling Lu, Jiyong Liang, Philip L. Lorenzi, Shanshan Bai, David H. Hawke, Jie Li, Turgut Dogruluk, Kenneth L. Scott, Eric Jonasch, Gordon B. Mills, Zhiyong Ding
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C199.
https://doi.org/10.1158/1535-7163.TARG-13-C199
Published: 01 November 2013
View articletitled, Abstract C199: Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules.
Journal Articles

Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Lixia Diao, Pan Tong, Jing Wang, You-Hong Fan, Yiling Lu, Wenbin Liu, Carmen Behrens, Ignacio I. Wistuba, John V. Heymach, John N. Weinstein, Gordon B. Mills, Lauren A. Byers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C117.
https://doi.org/10.1158/1535-7163.TARG-13-C117
Published: 01 November 2013
View articletitled, Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.
Journal Articles

Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC.

Kelsey P. Pendleton, Vivian W. Lui, Yiling Lu, Breean R. Gilbert, Kevin Levine, Gordon B. Mills, Jennifer R. Grandis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A23.
https://doi.org/10.1158/1535-7163.TARG-13-A23
Published: 01 November 2013
View articletitled, Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC.
Journal Articles

Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents

Zheng D. Liang, Yan Long, Wen-Bin Tsai, Siqing Fu, Razelle Kurzrock, Mihai Gagea-Iurascu, Fan Zhang, Helen H.W. Chen, Bryan T. Hennessy, Gordon B. Mills, Niramol Savaraj, Macus Tien Kuo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2483–2494.
https://doi.org/10.1158/1535-7163.MCT-12-0580
Published: 08 November 2012
View articletitled, Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents
Open the PDF for Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents in another window
Includes: Supplementary data
Journal Articles

Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

Jae-Ho Cheong, Eun Sung Park, Jiyong Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali Ravoori, Vikas Kundra, Jaffer Ajani, Ju-Seog Lee, Waun Ki Hong, Gordon B. Mills
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (12): 2350–2362.
https://doi.org/10.1158/1535-7163.MCT-11-0497
Published: 07 December 2011
View articletitled, Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models
Open the PDF for Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models in another window
Includes: Supplementary data
Journal Articles

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Ana M. Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A. Barrera, Octavio Burgues, Ana M. Lluch, Huiqin Chen, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (6): 1093–1101.
https://doi.org/10.1158/1535-7163.MCT-10-1089
Published: 08 June 2011
View articletitled, PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Open the PDF for PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer in another window
Journal Articles

Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer

David Luyimbazi, Argun Akcakanat, Priscilla F. McAuliffe, Li Zhang, Gopal Singh, Ana Maria Gonzalez-Angulo, Huiqin Chen, Kim-Anh Do, Yuhuan Zheng, Mien-Chie Hung, Gordon B. Mills, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (10): 2770–2784.
https://doi.org/10.1158/1535-7163.MCT-09-0980
Published: 10 October 2010
View articletitled, Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer
Open the PDF for Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer in another window
Includes: Supplementary data